Recent news for Synlogic includes financial reporting and contract awards relevant to its business operations.

• Synlogic reported a Q4 loss but topped revenue estimates as of March 19, 2024 [N1].
• The company secured a $1 million subcontract under the Air Force Research Lab as of December 27, 2023 [N1].

Synlogic's strong liquidity and net income in the latest quarter, despite zero revenue, indicate effective management of resources and potential value from strategic alternatives. The company's engagement with government research contracts and maintenance of robust governance frameworks provide a foundation for potential future opportunities. The presence of equity incentive plans aligns management and shareholder interests.

The absence of revenue and reliance on strategic alternatives such as mergers or sales indicate business model uncertainty. The company's delisting from Nasdaq may impact liquidity and investor perception. Limited workforce and ongoing expenses without commercial product revenue present risks to sustained operations. The biotechnology sector's inherent development and regulatory risks also apply.

Synlogic's moat is primarily based on its specialized biotechnology focus and strategic partnerships, including government contracts such as the subcontract with the Air Force Research Lab. The company's governance structure with experienced independent directors and financial oversight supports operational integrity. However, the company currently reports no revenue, indicating reliance on development-stage assets and strategic transactions rather than established commercial products.

• Business Model and Revenue Risk: Synlogic reported zero revenue for the quarter ended March 31, 2026, indicating reliance on development-stage activities and strategic alternatives rather than commercial sales [S2].
• Market Listing and Liquidity Risk: The company is no longer listed on Nasdaq, which may affect stock liquidity and investor access [S1].
• Operational Risk: With only one full-time employee focused on strategic transactions, operational capacity is limited [S1].
• Regulatory and Development Risk: As a biotechnology company, Synlogic faces risks related to product development, regulatory approvals, and market acceptance inherent in the sector [S1].

• Synlogic, Inc. is a Delaware corporation with its principal executive offices in Winchester, Massachusetts [S1].
• As of March 31, 2026, Synlogic had 11,698,919 shares of common stock outstanding [S1].
• The company is classified as a non-accelerated filer and a smaller reporting company [S1].
• Synlogic's Board of Directors consists of four members: Peter Barrett, Ph.D. (Chairman), James Flynn, Edward Mathers, and Richard P. Shea, all considered independent directors [S1].
• The Audit Committee has three members and oversees financial reporting and risk management; Richard Shea is the audit committee financial expert [S1].
• The Compensation Committee has two members and oversees compensation policies and equity incentive plans [S1].
• Synlogic had one full-time employee as of March 31, 2026, primarily engaged in strategic transaction assessment [S1].
• The company maintains corporate governance guidelines, a Code of Conduct, and a Whistleblower Policy [S1].
• Synlogic's financial snapshot as of March 31, 2026, includes cash and equivalents of $14.1 million, current assets of $14.6 million, current liabilities of $2.06 million, and a net income of $681,000 for the quarter [S2].
• The company reported zero revenue for the quarter ended March 31, 2026 [S2].
• Liquidity ratios as of March 31, 2026, include a current ratio of 7.08 and a cash ratio of 54.8, indicating strong liquidity [S2].
• Synlogic's earnings per share basic and diluted were $0.05 for the quarter ended March 31, 2026 [S2].
• The company is no longer listed on Nasdaq but remains a reporting company under the Securities Exchange Act of 1934 [S1].
• Synlogic has engaged in strategic alternatives to enhance stockholder value, including potential mergers or sales, as disclosed in SEC filings [S1].
• The company has indemnification agreements with its directors and executive officers and related party transaction policies [S1].
• Synlogic has multiple equity incentive plans including the 2025 Equity Incentive Award Plan with an evergreen provision for share increases [S1].
• Recent news includes Synlogic reporting a Q4 loss but topping revenue estimates as of March 19, 2024 [N1].
• Synlogic secured a $1 million subcontract under the Air Force Research Lab as of December 27, 2023 [N1].